Foghorn Therapeutics Inc.FHTXNASDAQ
LOADING
|||

Analyst Sentiment

Analysts lean bullish — 89% recommend buying.

Consensus Rating
Buy
9 analysts·Limited coverage
89%
Rating Distribution
Strong Buy
00%
Buy
889%
Hold
111%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 97% higher.

Bear Case
$11.00
+88%
Consensus
$11.50
+97%
Bull Case
$12.00
+105%
Price Range9 analysts
Low
Consensus
High
$11.00
$12.00
Current Target
Current Price
$5.85
Upside to Target
$5.65

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 18, 2025BTIG
Foghorn Therapeutics initiated with a Buy at BTIG
Target:$11.00
+137.1%from $4.64
Dec 3, 2025Stifel Nicolaus
Foghorn Therapeutics initiated with a Buy at Stifel
Target:$12.00
+170.3%from $4.44
Dec 17, 2024H.C. Wainwright
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright
Target:$13.00
+107.7%from $6.26
Sep 24, 2024Morgan Stanley
Foghorn Therapeutics (FHTX) PT Raised to $9 at Morgan Stanley
Target:$9.00
-3.4%from $9.32
Aug 19, 2024Evercore ISI
Foghorn Therapeutics initiated with an Outperform at Evercore ISI
Target:$20.00
+219.5%from $6.26
Jan 5, 2023BMO Capital
BMO Capital Initiates Coverage On Foghorn Therapeutics with Outperform Rating, Announces Price Target of $20
Target:$20.00
+206.3%from $6.53
Nov 21, 2022Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Foghorn Therapeutics, Lowers Price Target to $14
Target:$14.00
+77.9%from $7.87
Aug 23, 2022Morgan Stanley
Morgan Stanley downgrades Foghorn on uncertainty from clinical hold
Target:$15.00
+37.7%from $10.89